Flemming SkjÃ¸th

List of Publications by Year
in descending order

83 papers	3,963 citations	136740 32 h-index	118652 62 g-index
83 all docs	83 docs citations	83 times ranked	4728 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Dabigatran Etexilate and Warfarin in â€œReal-Worldâ€•Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2264-2273.	1.2	387
2	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, The, 2016, 353, i3189.	3.0	351
3	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ: British Medical Journal, 2017, 356, j510.	2.4	275
4	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 738-746.	1.2	272
5	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. Circulation, 2015, 132, 517-525.	1.6	225
6	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. Journal of the American Heart Association, 2017, 6, .	1.6	187
7	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. Circulation, 2018, 137, 832-840.	1.6	158
8	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AFÂWith 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. Journal of the American College of Cardiology, 2015, 65, 1385-1394.	1.2	141
9	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ, The, 2012, 345, e7097-e7097.	3.0	110
10	Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. American Journal of Medicine, 2014, 127, 650-656.e5.	0.6	100
11	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thrombosis and Haemostasis, 2015, 114, 826-834.	1.8	100
12	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 981-988.	1.8	99
13	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. American Journal of Medicine, 2013, 126, 640.e9-640.e17.	0.6	91
14	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Internal Medicine, 2017, 177, 563.	2.6	75
15	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke, 2015, 46, 2168-2174.	1.0	72
16	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Scientific Reports, 2016, 6, 27410.	1.6	67
17	Myocardial Ischemic Events in â€˜Real Worldâ€™ Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. American Journal of Medicine, 2014, 127, 329-336.e4.	0.6	63
18	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. PLoS ONE, 2014, 9, e114445.	1.1	54

#	Article	IF	Citations
19	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. Chest, 2014, 145, 559-566.	0.4	54
20	Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open, 2012, 2, e000975.	0.8	51
21	Alcohol intake and prognosis of atrial fibrillation. Heart, 2013, 99, 1093-1099.	1.2	51
22	Î²-Blockers in Atrial Fibrillation Patients With or Without Heart Failure. Circulation: Heart Failure, 2016, 9, e002597.	1.6	49
23	The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. PLoS ONE, 2017, 12, e0188482.	1.1	48
24	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. American Journal of Medicine, 2018, 131, 574.e13-574.e27.	0.6	46
25	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. JAMA Cardiology, 2017, 2, 872.	3.0	44
26	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. American Journal of Medicine, 2014, 127, 1172-1178.e5.	0.6	43
27	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. Chest, 2015, 147, 1651-1658.	0.4	43
28	Added Predictive Ability of the CHA ₂ DS ₂ VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 335-342.	0.9	41
29	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. Clinical Research in Cardiology, 2015, 104, 1088-1096.	1.5	36
30	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematology,the, 2017, 4, e237-e244.	2.2	36
31	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. Chest, 2014, 146, 1337-1346.	0.4	34
32	Nonâ€“Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. Stroke, 2019, 50, 939-946.	1.0	34
33	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating â€˜valvular heart diseaseâ€™ in a nationwide cohort study. Europace, 2019, 21, 33-40.	0.7	27
34	Wireless indoor tracking network based on Kalman filters with an application to monitoring dairy cows. Computers and Electronics in Agriculture, 2010, 72, 119-126.	3.7	25
35	Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation. Stroke, 2014, 45, 1331-1337.	1.0	25
36	Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy inÂNonvalvular Atrial Fibrillation Patients With 1ÂAdditional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). Journal of the American College of Cardiology, 2015, 66, 488-490.	1.2	24

#	Article	IF	Citations
37	Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open, 2017, 7, e018209.	0.8	23
38	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Advances, 2022, 6, 2967-2976.	2.5	23
39	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. PLoS ONE, 2014, 9, e113627.	1.1	22
40	Indirect comparison studies â€“ are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2012, 108, 405-406.	1.8	21
41	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). American Journal of Cardiology, 2020, 125, 48-54.	0.7	20
42	Atrial Fibrillation Patients Categorized as â€œNot for Anticoagulationâ€•According to the 2014 Canadian Cardiovascular Society Algorithm Are Not â€œLow Riskâ€• Canadian Journal of Cardiology, 2015, 31, 24-28.	0.8	17
43	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 787-794.e4.	0.6	17
44	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 789-795.	1.8	16
45	Does atrial pacing lead to atrial fibrillation in patients with sick sinus syndrome? Insights from the DANPACE trial. Europace, 2014, 16, 241-245.	0.7	16
46	Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2015, 114, 403-409.	1.8	15
47	Sex differences in risk of incident venous thromboembolism in heart failure patients. Clinical Research in Cardiology, 2019, 108, 101-109.	1.5	15
48	Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study. American Journal of Medicine, 2021, 134, 868-876.e5.	0.6	15
49	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. Scientific Reports, 2018, 8, 15805.	1.6	14
50	Risk of recurrence and bleeding in patients with cancerâ€associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. Cancer Medicine, 2019, 8, 1044-1053.	1.3	14
51	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. Circulation, 2021, 143, 907-920.	1.6	12
52	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. Annals of Thoracic Surgery, 2016, 101, 1494-1499.	0.7	11
53	Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation. Stroke, 2016, 47, 979-985.	1.0	11
54	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. ESC Heart Failure, 2018, 5, 319-326.	1.4	11

#	Article	IF	Citations
55	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. International Journal of Clinical Practice, 2018, 72, e13258.	0.8	11
56	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. European Journal of Vascular and Endovascular Surgery, 2022, 63, 285-294.	0.8	10
57	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. JAMA Network Open, 2022, 5, e2213945.	2.8	10
58	Visual appearance and CMT score of foremilk of individual quarters in relation to cell count of cows milked automatically. Journal of Dairy Research, 2005, 72, 49-56.	0.7	9
59	Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. Thrombosis and Haemostasis, 2016, 116, 524-529.	1.8	9
60	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. Thrombosis Research, 2020, 191, 1-8.	0.8	9
61	Using the CHA2DS2-VASc Score for Stroke Prevention in Atrial Fibrillation: A Focus on Vascular Disease, Women, and Simple Practical Application. Canadian Journal of Cardiology, 2015, 31, 820.e9-820.e10.	0.8	7
62	Dietary intake and adipose tissue content of long-chain nâ€“3 PUFAs and subsequent 5-y change in body weight and waist circumference. American Journal of Clinical Nutrition, 2017, 105, 1148-1157.	2.2	7
63	Clinical risk factors for retinal artery occlusions: a nationwide caseâ€“control study. International Ophthalmology, 2022, 42, 2483-2491.	0.6	7
64	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. Cerebrovascular Diseases, 2019, 48, 236-243.	0.8	6
65	Oral antiâ€coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. British Journal of Haematology, 2022, 197, 223-231.	1.2	6
66	Assigning diagnosis codes using medication history. Artificial Intelligence in Medicine, 2022, 128, 102307.	3.8	6
67	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 31-39.	1.4	5
68	Reply. Journal of the American College of Cardiology, 2013, 62, 946-947.	1.2	4
69	A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology. Thrombosis and Haemostasis, 2016, 116, 405-406.	1.8	4
70	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensityâ€Weighted Cohort Study. Journal of the American Heart Association, 2017, 6, .	1.6	4
71	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. American Journal of Medicine, 2021, , .	0.6	4
72	Twentyâ€year time trends in use of evidenceâ€based heart failure drug therapy in Denmark. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 30-38.	1.2	3

#	Article	IF	Citations
73	Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies. Cardiovascular Therapeutics, 2022, 2022, 1-11.	1.1	3
74	Genetic models for the inheritance of the silver colour mutation of foxes. Genetical Research, 1994, 64, 11-18.	0.3	2
75	Reply. Journal of the American College of Cardiology, 2013, 61, 596.	1.2	2
76	Towards Assigning Diagnosis Codes Using Medication History. Lecture Notes in Computer Science, 2020, , 203-213.	1.0	2
77	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. International Journal of Cardiology, 2016, 203, 785-790.	0.8	1
78	Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting. PharmacoEconomics - Open, 2022, 6, 483-494.	0.9	1
79	The Reply. American Journal of Medicine, 2014, 127, e21.	0.6	0
80	Causal Inference From Real-World Data. Journal of the American College of Cardiology, 2018, 72, 486-488.	1.2	0
81	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. American Journal of Medicine, 2021, 134, 67-75.e5.	0.6	0
82	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. Journal of Vascular Surgery, 2022, 75, 1119-1120.	0.6	0
83	Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study. Thrombosis and Haemostasis, 0, , .	1.8	0